DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0329704 A1 Melton Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0329704 A1 Melton Et Al US 201403297.04A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0329704 A1 Melton et al. (43) Pub. Date: Nov. 6, 2014 (54) MARKERS FORMATURE BETA-CIELLS AND Publication Classification METHODS OF USING THE SAME (51) Int. C. (71) Applicant: President and Fellows of Harvard College, Cambridge, MA (US) CI2O I/68 (2006.01) (52) U.S. C. (72) Inventors: Douglas A. Melton, Lexington, MA CPC ........ CI2O I/6881 (2013.01); C12O 2600/158 (US); Sinisa Hrvatin, Cambridge, MA (2013.01); C12O 2600/136 (2013.01) (US) USPC ............................... 506/9: 435/375; 435/6. 12 (21) Appl. No.: 14/228,959 (22) Filed: Mar 28, 2014 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 61/806,371, filed on Mar. Markers for mature B-cells and methods of using these mark 28, 2013. ers are disclosed. Patent Application Publication Nov. 6, 2014 Sheet 1 of 43 US 2014/0329704 A1 Figure A Patent Application Publication Nov. 6, 2014 Sheet 2 of 43 US 2014/0329704 A1 S. & S & y & s xxxxxxxxxxxxxNXXXXXXXXXXXXXXXXXXXXXXXXXXXaavaaXXXXXXVaaX XVSSSSSSSSSSSwwwVWWVSSNVSSNSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSNNNNNSNSWSW-Sawwas. SX SSSSSS. Saar-saxxxxx-xx-x-xxararaxaxaaraasarasarax xxxxxxxYxxxxxx xxxxxxx-x-xxxx xxxxxaararararararxxxYYYYYY &$3s S&SSSSSas a as S.S.a VXa $$$$&SSSSSS SSSSSSSS S$ssiss SS. S. S&S &Ss. s a S SSSSSSS S&SS SSSSS SSR 8SSSSSSSS swww.SSSSSSSSN\\\\\\\\\\\\\\\\xwww.www.www.www. S&SSR. SS Ssss S& SSay S$8 &. Ssss. S$8 &, s w SSSSS Rsssssss S S$&s & sts&sasaxawasawawaxaasawaxaasaaassavaasawawasawaxxxxx-aa-Saxxx-xxxxxxxxxxxxxxxxxxxxxxxxxWNNXxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxaa S s S8 SSS R assasswww.www.x.ysssssssssssss-XXXXX-XX. y xxxx xxxxwww.xxxxxxxxxxxxxws Figure 1B Patent Application Publication Nov. 6, 2014 Sheet 3 of 43 US 2014/03297.04 A1 sessertaiagy &oiagica: F Rs & airs: set adhesior lastasic scissio: resistassri:f Esi Riasissists exaces liaia rateris & Sisatirr strichsatiris striatellstafsir-ski its FSailize livai estatississis rates: SSSSSSSSS sex asssssssrsist & ississils sesses Fish. synapti Resilis is sport sRS 83 assists S. areer s its for projection sileipfirst 3. isit is assissisitari is 3:1 is 35ttistic: 8. 3. Seir 3.8xtin 83f.hgatesis S servershese reaisinese: it is fertisties s: sers Estitt is sistairyolefire-resississ & SS reprisix strisyesis S. sessistian shaftsrie assis . est-classistairs F3sitiq's ragstairs assissi-Fi SS regislatios sists of phoseysis issistic sectiot : re: Sigis retrinsifieferstatic ,88; as Ft. Erzgesesia 3.S. s.3 a factics crississistics secretir &S s SSSS 3. S. sapietrars risis SS S& g s &rare secretar s's fits parrassississist 3. s s & s Sx atter assisters seguilation is is siegeiopsier: estigis a ra:Firsssssssf sites ::Isstratigri sigssonsist s | 88 &ss: sess&s SSS-8 S. 3SRS & 3S & S& $8SS S&SSSSSSSS sess R888 expressists sists: GS. Patent Application Publication Nov. 6, 2014 Sheet 4 of 43 US 2014/03297.04 A1 - S: ES-tieries csis 8 FIGS 3A-3D Patent Application Publication Nov. 6, 2014 Sheet 5 of 43 US 2014/03297.04 A1 y FIGS. AA-AD Patent Application Publication Nov. 6, 2014 Sheet 7 of 43 US 2014/03297.04 A1 A Eira aii sets; tury is r fetal gafiseas J W. ris ; : . assig sesssssss N83 & ski & assssssss sei is Sisk &s X& 88s 3.323 Ssssss SKS &R8s 88.888: s.8 4. E: is $ 2. 8 gas ces e * As cess so *s s: i 33 is sis 3 sts gs: 8 sists 83S 3 is is Rsssssstates 83 3 : 'S issssssssss SS3 is is ty's sess sy : 88s 83 sists 8 : s &isis: .3 is kiss; secess ;: sixts: 8, s is: iss&issesses exist&six kissists' is 8:8-8, .---it-s-s-s E s SSS $ 8. Yesicle: & Sait...................a...s3. Electron transport chair. ..SS88 W assissississiestsiegsgess..............SS3 is trafghtisinesis. 883 : setti:ss:gs: R.E.g.:SESsis A seisrajestie's organization st:4S28 s Yifteegi sigsalise gaths 838 sistassie: Seigh9888&sis s: Figure 6 Patent Application Publication Nov. 6, 2014 Sheet 9 of 43 US 2014/03297.04 A1 Sin Patent Application Publication Nov. 6, 2014 Sheet 10 of 43 US 2014/03297.04 A1 | & 8 f SG 38 Sisirs FIGS. 9A-9C Patent Application Publication Nov. 6, 2014 Sheet 11 of 43 US 2014/03297.04 A1 AH2 SES. FR31 F. 8-3 SES E. 39S f 5 Ecs ET3 s G RESS SFX RERS SE: Ni KS RF CESS F-86Li E. HESS Fr. NFF FB SA S$ AEB E. S3 ESSR EE ESR 8S ES FE Fril.2 C3 O & -8 Foid charge icels, S6 ins: FIGS. 1 OA-1 OD Patent Application Publication Nov. 6, 2014 Sheet 12 of 43 US 2014/03297.04 A1 3. s ES-NS+ Festis ce:s. Acces , ofessi sage 82r his ess 82r is guitas.g. : S : Jes. Sisis. i i i S Hists&S8ins, 2 S. SSPs. S SS Ens. S iPS.56.irs. Š &sist setts. Assists. & it is stifs.3 Figure 11 Patent Application Publication Nov. 6, 2014 Sheet 13 of 43 US 2014/03297.04 A1 Patent Application Publication Nov. 6, 2014 Sheet 14 of 43 US 2014/0329704 A1 S o: {} NXS. o occo e o o O & e o () o cšS Patent Application Publication In?t,qži?ºquoo Patent Application Publication 6?,?ørnzIquooº Patent Application Publication Nov. 6, 2014 Sheet 18 of 43 US 2014/0329704 A Patent Application Publication Nov. 6, 2014 Sheet 19 of 43 US 2014/0329704 A1 • + Ta6?3ZT3opu as as N. as C. c. c. ? ext c. ca. o. o. at at as es d c. c e cy Patent Application Publication Nov. 6, 2014 Sheet 20 of 43 US 2014/0329704 A1 ca CX a was Yas c - es Patent Application Publication Nov. 6, 2014 Sheet 21 of 43 US 2014/0329704 A & gas 8:a::c c. c 2 to co - c. c. 9 to go o - c. c. a d S 3 ad Patent Application Publication US 2014/0329704 A1 Patent Application Publication Nov. 6, 2014 Sheet 23 of 43 US 2014/0329704 A1 n6||3ë),Ziquooº k we a 8x Patent Application Publication Nov. 6, 2014 Sheet 24 of 43 US 2014/03297.04 A1 ºquooZiean6!) Patent Application Publication US 2014/0329704 A1 Patent Application Publication Nov. 6, 2014 Sheet 26 of 43 US 2014/0329704 A1 Patent Application Publication Nov. 6, 2014 Sheet 27 of 43 US 2014/0329704 A Patent Application Publication Nov. 6, 2014 Sheet 28 of 43 US 2014/03297.04 A Patent Application Publication Nov. 6, 2014 Sheet 29 of 43 US 2014/0329704 A1 29 3 99 Patent Application Publication Nov. 6, 2014 Sheet 30 of 43 US 2014/0329704 A1 Patent Application Publication Patent Application Publication Nov. 6, 2014 Sheet 32 of 43 US 2014/0329704 A1 Patent Application Publication Patent Application Publication Nov. 6, 2014 Sheet 34 of 43 US 2014/0329704 A1 In67,3]©opg?û* Patent Application Publication Nov. 6, 2014 Sheet 35 of 43 US 2014/03297.04 A Patent Application Publication Nov. 6, 2014 Sheet 36 of 43 US 2014/0329704 A1 Patent Application Publication US 2014/03297.04 A1 Patent Application Publication Nov. 6, 2014 Sheet 38 of 43 US 2014/0329704 A1 Patent Application Publication Nov. 6, 2014 Sheet 39 of 43 US 2014/0329704 A &#########3 Patent Application Publication Nov. 6, 2014 Sheet 40 of 43 US 2014/0329704 A Patent Application Publication Nov. 6, 2014 Sheet 41 of 43 US 2014/0329704 A Patent Application Publication Nov. 6, 2014 Sheet 42 of 43 US 2014/0329704 A1 In67)9.op€†ºu* Patent Application Publication US 2014/0329704 A1 rab???exºTquoo US 2014/03297.04 A1 Nov. 6, 2014 MARKERS FORMATURE BETA-CIELLS AND transcriptome of pancreatic cells exhibits a pattern of expres METHODS OF USING THE SAME sion similar to the reference non-f-cell transcriptome. 0007. In some aspects, the present invention provides a RELATED APPLICATIONS method of identifying the functional maturity of B-cells, the 0001. This application claims the benefit of U.S. Provi method comprising: (a) obtaining a putative B-cellor a popu sional Application No. 61/806,371, filed Mar. 28, 2013. The lation of putative B-cells; and (b) detecting an expression entire teachings of the above application are incorporated level in the putative f3-cellor the population of putative B-cells herein by reference. of one or more genes listed in Table 2, Table 3 or Table 4, wherein: (i) an elevated level of expression of one or more GOVERNMENT SUPPORT genes listed in Table 1 or Table 2 in the putative B-cell or the population of putative B-cells indicates that the putative B-cell 0002 This invention was made with government support or the population of putative B-cells are functionally mature under 2 U01 DK072473-07 awarded by the National Insti B-cells; and (ii) an elevated level of expression of one or more tutes of Health. The government has certain rights in the genes listed in Table 3 or Table 4 in the putative B-cell or the invention. population of putative B-cells indicates that the putative B-cell or the population of putative B-cells are functionally imma BACKGROUND OF THE INVENTION ture f3-cells. 0003. The directed differentiation of stem cells has the 0008. In some aspects, the present invention provides a potential to produce B-cells for administration to individuals method of identifying mature B-cells, the method compris Suffering from diseases associated with n-cell abnormality ing: (a) obtaining a putative B-cell or a population of putative (e.g., diabetes). However, existing in vitro differentiation pro B-cells; and (b) detecting an expression level in the putative tocols often produce “B-like cells, which do not have the B-cell or the population of putative B-cells of one or more same functional properties as mature f3-cells.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Animal Cells Anterior Epidermis Anterior Epidermis A-Neural
    Anterior Epidermis Anterior Epidermis KH2012 TF common name Log2FC -Log(pvalue) Log2FC -Log(pvalue) DE in Imai Matched PWM PWM Cluster KH2012 TF common name Log2FC -Log(pvalue) Log2FC -Log(pvalue) DE in Imai Matched PWM PWM Cluster gene model Sibling Cluster Sibling Cluster Parent Cluster Parent Cluster z-score z-score gene model Sibling Cluster Sibling Cluster Parent Cluster Parent Cluster z-score z-score KH2012:KH.C11.485 Irx-B 1.0982 127.5106 0.9210 342.5323 Yes No PWM Hits No PWM Hits KH2012:KH.C1.159 E(spl)/hairy-a 1.3445 65.6302 0.6908 14.3413 Not Analyzed -15.2125 No PWM Hits KH2012:KH.L39.1 FoxH-b 0.6677 45.8148 1.1074 185.2909 No -3.3335 5.2695 KH2012:KH.C1.99 SoxB1 1.2482 73.2413 0.3331 9.3534 Not Analyzed No PWM match No PWM match KH2012:KH.C1.159 E(spl)/hairy-a 0.6233 47.2239 0.4339 77.0192 Yes -10.496 No PWM Hits KH2012:KH.C11.485 Irx-B 1.2355 72.8859 0.1608 0.0137 Not Analyzed No PWM Hits No PWM Hits KH2012:KH.C7.43 AP-2-like2 0.4991 31.7939 0.4775 68.8091 Yes 10.551 21.586 KH2012:KH.C1.1016 GCNF 0.8556 36.2030 1.3828 100.1236 Not Analyzed No PWM match No PWM match KH2012:KH.C1.99 SoxB1 0.4913 33.7808 0.3406 39.0890 No No PWM match No PWM match KH2012:KH.L108.4 CREB/ATF-a 0.6859 37.8207 0.3453 15.8154 Not Analyzed 6.405 8.6245 KH2012:KH.C7.157 Emc 0.4139 19.2080 1.1001 173.3024 Yes No PWM match No PWM match KH2012:KH.S164.12 SoxB2 0.6194 22.8414 0.6433 35.7335 Not Analyzed 8.722 17.405 KH2012:KH.C4.366 ERF2 -0.4878 -32.3767 -0.1770 -0.2316 No -10.324 9.7885 KH2012:KH.L4.17 Zinc Finger (C2H2)-18 0.6166 24.8925 0.2386 5.3130
    [Show full text]
  • Methylome and Transcriptome Maps of Human Visceral and Subcutaneous
    www.nature.com/scientificreports OPEN Methylome and transcriptome maps of human visceral and subcutaneous adipocytes reveal Received: 9 April 2019 Accepted: 11 June 2019 key epigenetic diferences at Published: xx xx xxxx developmental genes Stephen T. Bradford1,2,3, Shalima S. Nair1,3, Aaron L. Statham1, Susan J. van Dijk2, Timothy J. Peters 1,3,4, Firoz Anwar 2, Hugh J. French 1, Julius Z. H. von Martels1, Brodie Sutclife2, Madhavi P. Maddugoda1, Michelle Peranec1, Hilal Varinli1,2,5, Rosanna Arnoldy1, Michael Buckley1,4, Jason P. Ross2, Elena Zotenko1,3, Jenny Z. Song1, Clare Stirzaker1,3, Denis C. Bauer2, Wenjia Qu1, Michael M. Swarbrick6, Helen L. Lutgers1,7, Reginald V. Lord8, Katherine Samaras9,10, Peter L. Molloy 2 & Susan J. Clark 1,3 Adipocytes support key metabolic and endocrine functions of adipose tissue. Lipid is stored in two major classes of depots, namely visceral adipose (VA) and subcutaneous adipose (SA) depots. Increased visceral adiposity is associated with adverse health outcomes, whereas the impact of SA tissue is relatively metabolically benign. The precise molecular features associated with the functional diferences between the adipose depots are still not well understood. Here, we characterised transcriptomes and methylomes of isolated adipocytes from matched SA and VA tissues of individuals with normal BMI to identify epigenetic diferences and their contribution to cell type and depot-specifc function. We found that DNA methylomes were notably distinct between diferent adipocyte depots and were associated with diferential gene expression within pathways fundamental to adipocyte function. Most striking diferential methylation was found at transcription factor and developmental genes. Our fndings highlight the importance of developmental origins in the function of diferent fat depots.
    [Show full text]
  • A Pathologic Link Between Wilms Tumor Suppressor Gene, WT1, And
    Volume 10 Number 1 January 2008 pp. 69–78 69 www.neoplasia.com RESEARCH ARTICLE † Marianne K.-H. Kim*, Jacqueline M. Mason , A Pathologic Link between Wilms ‡ § Chi-Ming Li , Windy Berkofsky-Fessler , ∥ WT1 Le Jiang , Divaker Choubey¶, Paul E. Grundy#, Tumor Suppressor Gene, , ∥ and IFI161,2 Benjamin Tycko and Jonathan D. Licht* *Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; †The Campbell Family Institute for Breast Cancer Research at the Ontario, Cancer Institute, Ontario, Canada; ‡Translational Medicine, Amgen, Thousand Oaks, CA, USA; §Section of Bioinformatics, Genetics and Genomics, Hoffmann-La Roche Inc, Nutley, NJ, USA; ∥Institute for Cancer Genetics and Department of Pathology, Columbia University College of Physicians and Surgeons, New York, NY, USA; ¶University of Cincinnati, Cincinnati, OH, USA; #University of Alberta, Alberta, Canada Abstract The Wilms tumor gene (WT1) is mutated or deleted in patients with heredofamilial syndromes associated with the development of Wilms tumors, but is infrequently mutated in sporadic Wilms tumors. By comparing the micro- array profiles of syndromic versus sporadic Wilms tumors and WT1-inducible Saos-2 osteosarcoma cells, we iden- tified interferon-inducible protein 16 (IFI16), a transcriptional modulator, as a differentially expressed gene and a candidate WT1 target gene. WT1 induction in Saos-2 osteosarcoma cells led to strong induction of IFI16 expression and its promoter activity was responsive to the WT1 protein. Immunohistochemical analysis showed that IFI16 and WT1 colocalized in WT1-replete Wilms tumors, but not in normal human midgestation fetal kidneys, suggesting that the ability of WT1 to regulate IFI16 in tumors represented an aberrant pathologic relationship.
    [Show full text]
  • Human Pluripotent Stem Cell-Derived Ectomesenchymal Stromal Cells Promote More Robust Functional Recovery Than Umbilical Cord-De
    Human pluripotent stem cell-derived ectomesenchymal stromal cells promote more robust functional recovery than umbilical cord-derived mesenchymal stromal cells after hypoxic- ischaemic brain damage Jiawei Huang1,3*, Kin Pong U1,3*, Fuyuan Yang1, Zeyuan Ji1, Jiacheng Lin1,3, Zhihui Weng1, Lai Ling Tsang1,3, Tobias D Merson5, Ye Chun Ruan6, Chao Wan1,3, Gang Li2, Xiaohua Jiang1,3,4 1School of Biomedical Sciences, 2Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China. 3School of Biomedical Sciences Core Laboratory, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, PR China. 4Sichuan University – The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan, China. 5Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia. 6Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China. Running Title: Human ectomesenchymal stromal cells promote functional recovery in a rat HIE model *Corresponding author: Prof. Xiaohua JIANG, Email: [email protected] Address: Room 409A, Lo Kwee Seong Integrated Biomedical Sciences Building, Area 39, The Chinese University of Hong Kong, Shatin. Keywords: HIE, ectomesenchymal stromal cells, brain damage, regeneration, paracrine, ERK Abstract: Aims: Hypoxic-ischaemic encephalopathy (HIE) is one of the most serious complications in neonates and infants. Mesenchymal stromal cell (MSC)-based therapy is emerging as a promising treatment avenue for HIE. However, despite its enormous potential, the clinical application of MSCs is limited by cell heterogeneity, low isolation efficiency and unpredictable effectiveness. In this study, we examined the therapeutic effects and underlying mechanisms of human pluripotent stem cell-derived ectomesenchymal stromal cells (hPSC-EMSCs) in a rat model of HIE.
    [Show full text]
  • Supplement. Transcriptional Factors (TF), Protein Name and Their Description Or Function
    Supplement. Transcriptional factors (TF), protein name and their description or function. TF Protein name TF description/function ARID3A AT rich interactive domain 3A (BRIGHT-like) This gene encodes a member of the ARID (AT-rich interaction domain) family of DNA binding proteins. ATF4 Activating Transcription Factor 4 Transcriptional activator. Binds the cAMP response element (CRE) (consensus: 5-GTGACGT[AC][AG]-3), a sequence present in many viral and cellular promoters. CTCF CCCTC-Binding Factor Chromatin binding factor that binds to DNA sequence specific sites. Involved in transcriptional regulation by binding to chromatin insulators and preventing interaction between promoter and nearby enhancers and silencers. The protein can bind a histone acetyltransferase (HAT)-containing complex and function as a transcriptional activator or bind a histone deacetylase (HDAC)-containing complex and function as a transcriptional repressor. E2F1-6 E2F transcription factors 1-6 The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. EBF1 Transcription factor COE1 EBF1 has been shown to interact with ZNF423 and CREB binding proteins.
    [Show full text]
  • Computational Discovery of Transcription Factors Associated with Drug Response
    OPEN The Pharmacogenomics Journal (2016) 16, 573–582 www.nature.com/tpj ORIGINAL ARTICLE Computational discovery of transcription factors associated with drug response C Hanson1, J Cairns2, L Wang2 and S Sinha3 This study integrates gene expression, genotype and drug response data in lymphoblastoid cell lines with transcription factor (TF)-binding sites from ENCODE (Encyclopedia of Genomic Elements) in a novel methodology that elucidates regulatory contexts associated with cytotoxicity. The method, GENMi (Gene Expression iN the Middle), postulates that single-nucleotide polymorphisms within TF-binding sites putatively modulate its regulatory activity, and the resulting variation in gene expression leads to variation in drug response. Analysis of 161 TFs and 24 treatments revealed 334 significantly associated TF–treatment pairs. Investigation of 20 selected pairs yielded literature support for 13 of these associations, often from studies where perturbation of the TF expression changes drug response. Experimental validation of significant GENMi associations in taxanes and anthracyclines across two triple-negative breast cancer cell lines corroborates our findings. The method is shown to be more sensitive than an alternative, genome-wide association study-based approach that does not use gene expression. These results demonstrate the utility of GENMi in identifying TFs that influence drug response and provide a number of candidates for further testing. The Pharmacogenomics Journal (2016) 16, 573–582; doi:10.1038/tpj.2015.74; published online 27 October 2015 INTRODUCTION regulatory activities are associated with cellular response to The field of pharmacogenetics aims to understand the relationship cytotoxic treatments (Figure 1a), with the expectation that in the between individual variation at the genetic level and variation in future the response may be manipulated by intervening with the cellular or physiological response to a drug.
    [Show full text]
  • Integrated Transcriptomic, Phenotypic, and Functional Study Reveals Tissue-Specific Immune Properties of Mesenchymal Stromal
    Integrated Transcriptomic, Phenotypic, and Functional Study Reveals Tissue-Specific Immune Properties of Mesenchymal Stromal Cells Cédric Ménard, Joelle Dulong, David Roulois, Benjamin Hebraud, Léa Verdière, Céline Pangault, Vonick Sibut, Isabelle Bezier, Nadège Bescher, Céline Monvoisin, et al. To cite this version: Cédric Ménard, Joelle Dulong, David Roulois, Benjamin Hebraud, Léa Verdière, et al.. Inte- grated Transcriptomic, Phenotypic, and Functional Study Reveals Tissue-Specific Immune Prop- erties of Mesenchymal Stromal Cells. STEM CELLS, AlphaMed Press, 2020, 38 (1), pp.146-159. 10.1002/stem.3077. hal-02282131 HAL Id: hal-02282131 https://hal-univ-rennes1.archives-ouvertes.fr/hal-02282131 Submitted on 10 Sep 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Stem Cells Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells Journal: Stem Cells Manuscript ID Draft Wiley - Manuscript Type: Original Research Date Submitted by Forthe Peer Review n/a Author: Complete
    [Show full text]
  • Keep Your Fingers Off My DNA: Protein-Protein Interactions
    1 2 Keep your fingers off my DNA: 3 protein-protein interactions mediated by C2H2 zinc finger domains 4 5 6 a scholarly review 7 8 9 10 11 Kathryn J. Brayer1 and David J. Segal2* 12 13 14 15 16 17 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 18 Tucson, AZ, 85721. 19 2Genome Center and Department of Pharmacology, University of California, Davis, CA, 95616. 20 21 22 23 24 *To whom correspondence should be addressed: 25 David J. Segal, Ph.D. 26 University of California, Davis 27 Genome Center/Pharmacology 28 4513 GBSF 29 451 E. Health Sciences Dr. 30 Davis, CA 95616 31 Tel: 530-754-9134 32 Fax: 530-754-9658 33 Email: [email protected] 34 35 36 Running header: C2H2 ZF interactions with proteins 37 38 Keywords: transcription factors, protein-DNA interactions, protein chemistry, structural biology, 39 functional annotations 40 41 Abstract: 154 words 42 Body Text: 5863 words 43 Figures: 9 44 Tables: 5 45 References: 165 46 C2H2 ZF interactions with proteins Brayer and Segal - review 46 ABSTRACT 47 Cys2-His2 (C2H2) zinc finger domains were originally identified as DNA binding 48 domains, and uncharacterized domains are typically assumed to function in DNA binding. 49 However, a growing body of evidence suggests an important and widespread role for these 50 domains in protein binding. There are even examples of zinc fingers that support both DNA and 51 protein interactions, which can be found in well-known DNA-binding proteins such as Sp1, 52 Zif268, and YY1. C2H2 protein-protein interactions are proving to be more abundant than 53 previously appreciated, more plastic than their DNA-binding counterparts, and more variable and 54 complex in their interactions surfaces.
    [Show full text]
  • Targeted Single-Cell RNA Sequencing of Transcription Factors Enhances the Identification of Cell Types and Trajectories
    Downloaded from genome.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press Method Targeted single-cell RNA sequencing of transcription factors enhances the identification of cell types and trajectories Alexandra Pokhilko,1,9 Adam E. Handel,1,9 Fabiola Curion,2 Viola Volpato,3 Emma S. Whiteley,4 Sunniva Bøstrand,4 Sarah E. Newey,4 Colin J. Akerman,4 Caleb Webber,3 Michael B. Clark,5,6 Rory Bowden,2,7,8 and M. Zameel Cader1 1Translational Molecular Neuroscience Group, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DS, United Kingdom; 2Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, United Kingdom; 3UK Dementia Research Institute, Cardiff University, Cardiff, CF24 4HQ, United Kingdom; 4Department of Pharmacology, University of Oxford, Oxford, OX1 3QT, United Kingdom; 5Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, United Kingdom; 6Centre for Stem Cell Systems, Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Victoria 3010, Australia; 7The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; 8University of Melbourne, Department of Medical Biology, Parkville, Victoria 3052, Australia Single-cell RNA sequencing (scRNA-seq) is a widely used method for identifying cell types and trajectories in biologically heterogeneous samples, but it is limited in its detection and quantification of lowly expressed genes. This results in missing important biological signals, such as the expression of key transcription factors (TFs) driving cellular differentiation. We show that targeted sequencing of ∼1000 TFs (scCapture-seq) in iPSC-derived neuronal cultures greatly improves the bio- logical information garnered from scRNA-seq.
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • Molecular Genetic Characterization of Retinoblastoma Tumors Lacking Rb1 Mutations
    MOLECULAR GENETIC CHARACTERIZATION OF RETINOBLASTOMA TUMORS LACKING RB1 MUTATIONS by Jennifer Yvonne Kennett B.Sc., Simon Fraser University, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in The Faculty Of Graduate Studies (Pathology and Laboratory Medicine) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) December 2012 © Jennifer Yvonne Kennett, 2012 Abstract Retinoblastoma is a rare childhood cancer of the retina and is the most common intraocular tumor in children. Classically, retinoblastoma results from biallelic loss of the RB1 tumor suppressor gene. As with other cancer types, dysregulation of a single gene alone is not considered sufficient for complete transformation to malignancy. Frequent regions of genetic alteration harbouring additional genes, implicated in retinoblastoma oncogenesis and progression, include chromosomes 1q, 2p, 6p, 13q and 16q. Sensitive molecular genetic screening techniques are capable of identifying RB1 mutations in 98% of unilateral retinoblastoma tumors. The remaining 2% harbour no identifiable RB1 inactivating alterations, and therefore molecular interrogation of these cases would likely reveal alternative genetic events driving retinoblastoma tumorigenesis in the absence of RB1 inactivation. Towards this objective, in this thesis work, I describe genetic alterations identified by tiling path array comparative genomic hybridization in a rare sample set composed of 23 RB1+/+ tumors. In addition to gene disruption by copy number alteration, mechanisms of gene disruption resulting in no overall change in copy number or change in copy number with allelic imbalance were also investigated utilizing genome-wide SNP array analysis on five of the RB1+/+ tumors. The most striking recurrent genetic alteration identified in retinoblastoma tumors lacking RB1 inactivating mutations, was focal high-level MYCN amplification, which occurred at a frequency of approximately 48%.
    [Show full text]